Robert Williams - Laboratory Independent Director
| LH Stock | USD 207.94 0.03 0.01% |
Director
Dr. Robert Sanders Williams, M.D., is Independent Director of the Company. Dr. Williams has served as President Emeritus of The J. David Gladstone Institutes since January 1, 2018. Prior to this appointment, he was president of The J. David Gladstone Institutes since November 2009, and he served as Chief Executive Officer of The J. David Gladstone Foundation until December 31, 2018. Dr. Williams also currently is Professor of Medicine at the University of California San Francisco, Professor of Medicine at Duke University, and Senior Advisor for science and technology, Duke University. Dr. Williams served Duke University between 2001 and 2010 as Dean of the School of Medicine, Senior Vice Chancellor, Senior Advisor for International Strategy, and founding Dean of the DukeNUS Graduate Medical School Singapore. He has served previously as President of the Association of University Cardiologists, Chairman of the Research Committee of the American Heart Association, on the editorial boards of leading biomedical journals, on the Advisory Committee to the Director of the National Institutes of Health and on the board of external advisors of the National Heart, Lung and Blood Institute. Dr. Williams was a director of BristolMeyers Squibb Company from 2006 until May 2013 and was a director of Amgen, Inc. since October 2014 since 2007.
| Age | 72 |
| Tenure | 17 years |
| Address | 358 South Main Street, Burlington, NC, United States, 27215 |
| Phone | 336 229 1127 |
| Web | https://www.labcorp.com |
Laboratory Management Efficiency
The company has Return on Asset (ROA) of 0.0377 % which means that for every $100 of assets, it generated a profit of $0.0377. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.0423 %, which means that it produced $0.0423 on every 100 dollars invested by current stockholders. Laboratory's management efficiency ratios could be used to measure how well Laboratory manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to 0.05. The current Return On Capital Employed is estimated to decrease to 0.08. As of now, Laboratory's Total Current Assets are increasing as compared to previous years. The Laboratory's current Other Assets is estimated to increase to about 531.7 M, while Non Currrent Assets Other are projected to decrease to under 270.8 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Gary Hendrickson | Waters | 64 | |
| Jenne Britell | Quest Diagnostics Incorporated | 74 | |
| Laurie Glimcher | Waters | 66 | |
| William Mitchell | Humana Inc | 73 | |
| Shawn Bevec | Quest Diagnostics Incorporated | N/A | |
| Amy Wendell | Hologic | 57 | |
| Frank DAmelio | Humana Inc | 63 | |
| John Baldwin | Quest Diagnostics Incorporated | 65 | |
| Elaine Ullian | Hologic | 68 | |
| Christopher Kuebler | Waters | 66 | |
| John Herrell | Universal Health Services | 75 | |
| Christiana Stamoulis | Hologic | 47 | |
| Lawrence Levy | Hologic | 78 | |
| Gail Wilensky | Quest Diagnostics Incorporated | 76 | |
| Ludwig Hantson | Hologic | 55 | |
| Dan Haemmerle | Quest Diagnostics Incorporated | N/A | |
| Al Kildani | Hologic | N/A | |
| Edward Conard | Waters | 63 | |
| Linda Baddour | Waters | 62 | |
| Vicky Gregg | Quest Diagnostics Incorporated | 65 | |
| Wayne Wilson | Hologic | 65 | |
Management Performance
| Return On Equity | 0.0423 | ||||
| Return On Asset | 0.0377 |
Laboratory Leadership Team
Elected by the shareholders, the Laboratory's board of directors comprises two types of representatives: Laboratory inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Laboratory. The board's role is to monitor Laboratory's management team and ensure that shareholders' interests are well served. Laboratory's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Laboratory's outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Klitgaard, President- Enlighten Health | ||
| Paul Surdez, IR Contact Officer | ||
| Deborah Tanner, CEO - Covance Drug Development (Covance) | ||
| Stephen Anderson, Vice President Investor Relations | ||
| Sanders Williams, Independent Director | ||
| JD MD, President EVP | ||
| Amy Summy, Executive Vice President Chief Marketing Officer | ||
| Mark Schroeder, Executive Vice President and Presidentident of Diagnostics Laboratory Operations and Global Supply Chain | ||
| Robert Pringle, Senior Treasurer | ||
| Peter Wilkinson, Senior Vice President, Chief Accounting Officer | ||
| Lisa Uthgenannt, Chief Human Resource Officer, Senior Vice President | ||
| Brian Caveney, Executive Vice President, President, Diagnostics and Chief Medical Officer | ||
| D Gilliland, Independent Director | ||
| Gary Huff, CEO, LabCorp Diagnostics | ||
| JeanLuc Belingard, Independent Director | ||
| Clarissa Willett, IR Contact Officer | ||
| Peter Neupert, Lead Independent Director | ||
| Robert Williams, Independent Director | ||
| Megan MPH, Executive Officer | ||
| Chas Cook, VP Relations | ||
| Garheng Kong, Independent Director | ||
| Gary Gilliland, Independent Director | ||
| David King, Chairman of the Board, President, Chief Executive Officer | ||
| Adam Schechter, Chairman of the Board, President, Chief Executive Officer | ||
| Mark Brecher, Senior Vice President Chief Medical Officer | ||
| Samuel Eberts, Senior Vice President Chief Compliance Officer, Secretary, Chief Legal Officer | ||
| Sandra Vaart, Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary | ||
| Edward Dodson, Chief Accounting Officer and Sr. VP | ||
| Robert Mittelstaedt, Lead Independent Director | ||
| Anita Graham, Executive Officer | ||
| Glenn Eisenberg, Chief Financial Officer, Executive Vice President | ||
| Lance Berberian, Executive Vice President, Chief Technology Officer, Chief Information Officer | ||
| Judith Seltz, Chief Human Resource Officer, Executive Vice President | ||
| Michelle Abelson, Laboratory Operations | ||
| Jonathan DiVincenzo, Executive International | ||
| John Ratliff, Chief Executive Officer - Covance Drug Development | ||
| Kerrii Anderson, Independent Director | ||
| Paul MD, Ex Devel | ||
| Marcia Eisenberg, Chief VP | ||
| John Treadwell, Vice Initiatives | ||
| Kathryn Wengel, Independent Director | ||
| Paul Kirchgraber, Executive Vice President and Chief Executive Officer - Covance Drug Development | ||
| James Boyle, Executive VP and CEO of Labcorp Diagnostics | ||
| Richelle Parham, Independent Director | ||
| Jeffrey Davis, Independent Director | ||
| Christin ODonnell, Vice Relations | ||
| Deborah SesokPizzini, SVP Officer | ||
| Scott Frommer, Vice President - Investor Relations | ||
| MPH MD, Pres VP |
Laboratory Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Laboratory a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0423 | ||||
| Return On Asset | 0.0377 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 22.92 B | ||||
| Shares Outstanding | 84.13 M | ||||
| Shares Owned By Insiders | 0.34 % | ||||
| Shares Owned By Institutions | 99.03 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | 12.69 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Laboratory of. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Laboratory information on this page should be used as a complementary analysis to other Laboratory's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Complementary Tools for Laboratory Stock analysis
When running Laboratory's price analysis, check to measure Laboratory's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Laboratory is operating at the current time. Most of Laboratory's value examination focuses on studying past and present price action to predict the probability of Laboratory's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Laboratory's price. Additionally, you may evaluate how the addition of Laboratory to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance |
Is Laboratory's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Laboratory. If investors know Laboratory will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Laboratory listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.46) | Dividend Share 2.88 | Earnings Share 4.33 | Revenue Per Share 139.628 | Quarterly Revenue Growth 0.035 |
The market value of Laboratory is measured differently than its book value, which is the value of Laboratory that is recorded on the company's balance sheet. Investors also form their own opinion of Laboratory's value that differs from its market value or its book value, called intrinsic value, which is Laboratory's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Laboratory's market value can be influenced by many factors that don't directly affect Laboratory's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Laboratory's value and its price as these two are different measures arrived at by different means. Investors typically determine if Laboratory is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Laboratory's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.